SCHEMBL5258236

SCHEMBL5258236

CNc1ccnc(Nc2cccc(-c3nc4ccccc4s3)c2)n1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 5/20 0.78
FLT4 P35916 4/20 0.72
KDR P35968 4/20 0.72
AURKB Q96GD4 4/20 0.72
EGFR P00533 3/20 0.72
INSR P06213 2/20 0.72
IGF1R P08069 2/20 0.72
SRC P12931 2/20 0.72
RAB9A P51151 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
GAA P10253 2/20 0.54
KDM4E B2RXH2 2/20 0.54
NPC1 O15118 2/20 0.54
APP P05067 3/20 0.51
TEK Q02763 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
GLA P06280 1/20 0.50
EPHB4 P54760 1/20 0.50
ERBB2 P04626 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5257695 0.91 KDR (0.78) AURKAFLT4KDRAURKBEGFR
SCHEMBL14621212 0.88 AURKA (0.65) AURKAFLT4KDRAURKBEGFR
SCHEMBL5259629 0.87 AURKA (1.00) AURKAFLT4KDRAURKBEGFR
SCHEMBL5263593 0.84 AURKA (1.00) AURKAFLT4KDRAURKBEGFR
SCHEMBL5259397 0.79 SMN1; SMN2 (0.60) AURKAFLT4KDRAURKBEGFR
SCHEMBL5260039 0.79 AURKA (0.80) AURKAFLT4KDRAURKBEGFR
SCHEMBL5259732 0.78 KDR (1.00) AURKAFLT4KDRAURKBEGFR
SCHEMBL24586958 0.78 RAB9A (0.65) AURKAFLT4KDRAURKBEGFR
SCHEMBL5260406 0.76 RAB9A (0.61) AURKAFLT4KDRAURKBEGFR
SCHEMBL5260799 0.76 FLT4 (1.00) AURKAFLT4KDRAURKBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 AURKA 493/4885FLT4 1772/4885KDR 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.